To conclude, our findings suggested that targeting the PD-1/PD-L1 pathway boosts antigen-specific responses to pathogens other than HIV in infected persons on ART, and may be considered as a strategy to prevent the loss of vaccine-induced immunity in HIV infection. Here, CD274 is linked to HIV infectious disease.